FDA approved a PD-L1 companion test to identify patients with ovarian, fallopian tube or primary peritoneal cancer who may receive first-line Keytruda. The U.S. Food and Drug Administration (FDA) has ...
Scientific advances and more accessible genetic testing have made removal of the ovaries and fallopian tubes the recommended way to treat certain people at high risk of ovarian cancer. The results of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results